momelotinib vs. ruxolitinib in myelofibrosis patients with thrombocytopenia
Published 3 years ago • 418 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
1:59
pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia
-
3:05
ruxolitinib, pacritinib, fedratinib or momelotinib for thrombocytopenic patients with myelofibrosis
-
5:12
ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
-
2:07
real-world use of ruxolitinib in patients with myelofibrosis with anemia or thrombocytopenia
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
21:06
lymphoid series part 1
-
3:40
pros and cons of ruxolitinib for the treatment of mpns
-
2:44
myelofibrosis: jenson shares his experience
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
2:00
the role of fedratinib in 2024 and beyond
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
3:48
efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from momentum
-
2:14
ruxolitinib combinations in patients with myelofibrosis
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
3:39
efficacy of navitoclax with ruxolitinib in myelofibrosis patients
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
2:10
phase i study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
-
3:43
momelotinib: a promising drug for patients with myelofibrosis
-
1:01
clinical outcomes for patients with myelofibrosis after transition from ruxolitinib to momelotinib